2023 Chronic Disease Consulting Diabetes 
Today's Hospitalist
JUNE 7, 2025
THE BLOCKBUSTER GLP-1 receptor agonists are a transformative class of medications increasingly tied to better outcomes across a variety of conditions and organ systems, not just in patients with obesity and type 2 diabetes. Published in May 2024, the FLOW trial , for instance, looked at patients with diabetes and advanced kidney disease.
GeriPal
JANUARY 16, 2025
Eric 13:00 I also love that too, because even on our inpatient ballot of care consult service, whenever somebody says that they’re unrepresented or they don’t have a surrogate, we never believe that until we usually look up. It’s been revised in 2023. Decision making hierarchies by default. What do I do?
Expert insights. Personalized for you.
66 
Let's personalize your content